Niemann-Pick disease type C (NP-C) is a rare autosomal recessive disorder caused by mutations in the NPC1
INTRODUCTION
Niemann-Pick disease type C (NP-C, OMIM 257220) is an autosomal recessive lysosomal lipid storage disorder with extremely heterogeneous clinical representation. NP-C is a rare panethnic disease with a minimal calculated incidence of 1:150 000 live births. It is caused by mutations in the NPC1 and/or NPC2 genes (1, 2) . Approximately 95% of NP-C cases have mutations in the NPC1 gene (MIM 607623; chromosome 18q11-q12), encoding a large glycoprotein (1278 amino acids) with 13 transmembrane domains that resides primarily in membrane of late endosomes (LE). The rest of patients have mutations in the NPC2 gene (MIM 601015; chromosome 14q24.3) encoding a soluble and glycosylated protein present in the LE lumen. In healthy individuals, NPC1 and NPC2 act together as a cellular duo that catalyzes mobilization of cholesterol and its export out of the LEs (1) (2) (3) (4) (5) . Consequently, mutations in one or both genes lead to accumulation of unesterifi ed cholesterol and glycosphingolipids in late endosomes/lysosomes causing various neurovisceral symptoms (1, 6) . Today, the NP-C disease variation database lists 252 disease-causing sequence variants of the NPC1 gene and 18 of the NPC2 gene (November, 2013) (7) . It has been shown that mutations correlate with neurologic forms of the disease, and nonsense and frameshift mutations are causing the most severe neurologic course (1) . NP-C has extremely heterogeneous clinical presentation, with a wide range of symptoms that are not specifi c for the disease. The age at onset also varies greatly with neonatal, early infantile (age at onset 2 months to 2 years), late infantile (2-6 years), juvenile (6-15 years) and adult (>15 years) forms. Further, lifespan of patients can be from few days to over 60 years of age, with the majority of patients dying between 10 and 25 years of age. The major systemic symptoms include foetal ascites/hydrops, neonatal cholestasis and (hepato)splenomegaly. Neurologic symptoms are delay in motor milestones and hypotonia for early infantile form of the disease; gait problems, clumsiness, speech delay and cataplexy for late infantile form; school problems, ataxia, seizures and cataplexy for juvenile form; and psychiatric problems, ataxia, dystonia and dementia for adult form. Vertical supranuclear gaze palsy can also appear in all forms of the disease (1, 8, 9) . After NP-C has been suspected based on clinical symptoms, it is necessary to confi rm the diagnosis by histologic, biochemical and genetic tests. Due to impaired intracellular cholesterol transport in NP-C, esterification of exogenously administered cholesterol by cultured skin fi broblasts is defi cient at 4.5 or 6 hours. Furthermore, fl uorescent fi lipin staining shows accumulation of unesterifi ed cholesterol in lysosomes (1, 8) . Electron microscopy (EM) of skin biopsy may reveal the presence of sequestrated lipids in lysosomes (10) . Also, because of prenatal diagnosis or identifi cations of carriers in the family, it is advisable to do genetic testing (1, 8) .
The accurate diagnosis of this rare disease is often a prolonged process, with a high probability of misdiagnosis due to heterogeneity and non-specifi city of its clinical symptoms that arise and progress over varied periods of time (8, 11) . Further, for many countries including Croatia, there are no reported NP-C cases to date. Therefore, the aim of this paper is to improve clinical practice and understanding of NP-C. As an illustration, we present the fi rst cases of NP-C disease recorded in Croatia, with emphasis on the importance of early and accurate diagnosis for the patient and for the family.
SUBJECTS AND METHODS
Two siblings, a female born in 1987 and a male born in 1992, having juvenile and late infantile form of NP-C, respectively, were born after uneventful pregnancy and delivery. Birth parameters were normal (body weight, body length, head circumference, APGAR). Both had neonatal jaundice, hepatosplenomegaly and cholestasis that was resolved in a few months following birth. Developmental milestones were reached normally, until the onset of the disease.
The girl was 5 years old when hepatosplenomegaly was noticed and had lower interest, concentration and poor drawing abilities. At the age of seven years, before entering school, tests were performed and mild intellectual disability was shown (reduced school program). Dysrhythmic electroencephalogram (EEG) was recorded, while computed tomography (CT) of the brain and laboratory tests were still normal. At the age of nine, the aspartate transaminase (AST) level was at the upper limit of the reference range (47 U/L), without hepatosplenomegaly and with normal other liver tests. She did not have a phenotype or laboratory signs of hypoplasia/atresia of bile ducts or cholestatic liver disease. Magnetic resonance (MR) of the brain showed periventricular demyelination, fi rst in frontal and then in occipital region, but no cortical atrophy. Leukodystrophy of Pelizaeus-Merzbacher and white-matter disease were suspected. Neurologic symptoms developed, including clumsiness, dystonic/athetotic movements, dysmetria, ataxic/spastic gait, increased muscle tone and deep tendon refl exes, slurred, nasal and poor speech, supported walk, and paresis of upward gaze. She had dysrhythmic EEG; dyssynchrony of visual evoked potentials (VEP). Brain stem evoked response audiometry (BERA), electromyoneurography (EMNG), cerebrospinal fl uid (CSF) and skin biopsy by EM were normal. Mitochondrial, peroxisomal and Wilson diseases were excluded based on laboratory testing. Catalytic activities of β-hexosaminidase A and A and B (βHEX A A&B), β-galactosidase (βGAL), β-glucosidase (βGLUC) and arylsulfatase A (ARILSA) were within the reference values. Grand mal seizure in duration of 5 minutes occurred at the age of 9 years and 9 months. Therapy with valproic acid, carbamazepine and phenobarbital was started. At the time, NP-C was suspected and the second skin biopsy revealed lipid inclusions in dermal axons leading to the diagnosis. The diagnosis of NP-C was confi rmed in cultured fi broblasts by fi lipin test and very low esterifi cation of exogenously administered cholesterol. Therapy included low cholesterol diet, lovastatin, cholestyramine and niacin. At the age of 10 years and 5 months, the clinical picture was progressively deteriorating, with brain MR showing not only demyelination but also cortical atrophy. Intractable epilepsy developed. Therapy with vigabatrin and neurontin was introduced, low cholesterol diet was stopped. When she was 11 years old, she was in vegetative state and percutaneous endoscopic gastrostomy (PEG) had to be applied with supportive measures and palliative care. She also had insomnia. She died when she was 11 years and 10 months old. Autopsy revealed bal-looning of neuronal cytoplasm and lipid laden foam cells in the spleen, liver, lymph nodes and bone marrow.
The male sibling had earlier onset and faster progress of the disease (Figure 1 ). At the time he was born, his elder sister had not yet been correctly diagnosed as NP-C. After birth, he had neonatal jaundice, hepatosplenomegaly and cholestasis that was resolved in a few months following birth. When the boy was 1.5 year old, he fell from 3-m height and sustained head trauma and leg fracture. In his early childhood, he suff ered frequent viral infections. Despite normal early development, the fi rst symptoms of NP-C appeared as very slow speech development (2-3 words at 3.5 years). At the age of 4 years, behavioral and cognitive problems appeared, such as hyperactivity, poor memory and slurred speech. Logotherapy was started. He had hepatosplenomegaly, AST 44 U/L and bile acid 10 mmol/L. Other liver tests were normal and there were no phenotype/laboratory signs for hypoplasia/atresia of bile ducts and cholestatic liver disease. Skin biopsy was done when the boy was 5 years and 8 months old. In contrast to the results of his sister's skin biopsy, no lipid inclusions were found. Nevertheless, in fi broblasts fi lipin test was positive and exogenously administered cholesterol esterifi cation defective, leading to the diagnosis of NP-C. Although EEG, VEP and laboratory tests were normal at the time, IQ was 86, and MR revealed demyelination in the occipital part of the brain. Therapy with lovastatin, cholestyramine, niacin and lowcholesterol diet was administered. At the age of 6 years, epilepsy fi ts started, EEG was dysrhythmic, dysarthria and ataxia appeared. He was enrolled in the school for children with special needs (mild intellectual disability). Carbamazepine and vigabatrin were added to therapy, while cholesterol-lowering therapy was stopped since there was no evidence for amelioration of neurologic symptoms. He died when he was 10 years and 3 months old.
Molecular analysis at fi rst excluded the most prevalent NP-C causing I1061T mutation (12) (by courtesy of M.T. Vanier) and after the deaths it was found that both siblings were compound heterozygotes for two disease-causing mutations in the NPC1 gene (courtesy of S. Calandra). NPC1 allele with A3467G mutation in exon 22 codes for defective protein with the amino acid serine instead of asparagine at position 156 (N1156S), while C2764T in exon 18 causes nonsense mutation, i.e. conversion of the amino acid glutamine into a stop codon (Q922X). The probands' mother was heterozygous for Q922X mutation and probands' father was heterozygous for N1156S mutation.
DISCUSSION AND CONCLUSIONS
Niemann-Pick disease type C is a rare panethnic disease, but data on disease-causing mutations were collected mostly in Western Europe and the USA (7). This has led us to present the fi rst case of siblings with NP-C in Croatia with the aim to improve clinical practice and understanding of NP-C in the region. 
Molecular analyses showed that both siblings were compound heterozygotes for two disease-causing mutations in the NPC1 gene, leading to the production of defective NPC1 protein variants with N1156S and Q922X mutations. The N1156S mutation is positioned within the luminal portion of NPC1, between the 10 th and 11 th transmembrane domain. It seems that this allele has a considerably wide distribution because, besides the cases presented here, it has been found in several patients from Spain (13), United Kingdom (14) , Israel (15) and elsewhere (16) . Only the Israeli patient was homozygous and therefore off ered an opportunity to study the eff ect of this particular mutation on the phenotype. This patient had juvenile onset of symptoms (hepatosplenomegaly at 4 months), but otherwise showed moderate clinical phenotype in comparison to our siblings. Therefore, we presume that in the case of siblings presented here, Q922X mutation (17) , causing the formation of a truncated NPC 1 protein of 921 amino acids, had a more severe impact on the clinical outcome than N1156S mutation. Correlation of nonsense mutations of NPC1 and early neurologic onset and shorter life span was suggested earlier (18) . Interestingly, this mutation was found only in genomic DNA, while in associated cDNA it was not detectable (data not shown). This raises the possibility of degradation of mRNA containing premature stop codon (17) . In the analyzed family, direct consanguinity was not detected, but both parents trace their origin from the island of Krk: maternal grandparents have second cousins from the village of Linardići (Krk), while paternal grandfather is from Punat (Krk). It is well known that some villages on the island of Krk present small, isolated and highly inbred populations, therefore with a high chance of unusually high frequencies of otherwise rare genetic variants (e.g., hereditary dwarfi sm) (19) .
Although both siblings were of the same NPC1 genotype, phenotypic diff erences could be observed ( Figure 1 ). As described in more detail above, in the neonatal and early infantile period both siblings had transient jaundice and hepatosplenomegaly. In the girl, symptoms appeared on the 20 th day of life and lasted for 3 months, and the boy had symptoms from the birth, the symptoms were more pronounced and lasted for 6 months. Afterwards, both siblings had normal developmental milestones. At the age of 5 years, a loss of interest and concentration with poor drawing was noticed in the girl. In comparison, the boy exhibited behavioral problems, hyperactivity, poor memory and slurred speech at the age of 4 years. At the age of 7 years, the girl had dysrhythmic EEG, normal CT of the brain and because of borderline intellectual disability she was admitted to the regular school with reduced school program. The boy had 6.5 years of age, dysarthria and ataxia were observed, and he was admitted to the school for children with special needs because of mild intellectual disability. When the girl was 9 years old, there was no hepatosplenomegaly and there were no laboratory signs of hypoplasia or atresia of bile ducts or cholestatic liver disease. At the same time, gastroenterological examination performed in the boy at the age of 4 years showed mild hepatosplenomegaly, but no laboratory signs of liver disease. The girl learned to write and read, but at the age of 9 years and 4 months she stopped to go to school because of dystonia, athetosis, dysmetria, ataxia, spastic gait, slurred nasal and poor speech, and MR of the brain showed high signal in the periventricular occipital region. Extensive neuropediatric workup was done and results were normal including EM skin biopsy, only some changes were seen on EEG and VEP. Because of the progression of demyelination in the frontal and occipital part and because of the fi rst grand mal attack at the age of 9 years and 9 months, paresis of upward gaze and deterioration of motor skills, skin biopsy was repeated and lipid inclusions in dermal axons were found suggesting the diagnosis of NP-C. The boy had his fi rst epileptic fi t at a younger age (6 years), the fi rst MR of the brain at the age of 7 years showing demyelination in the occipital part; EEG, VEP and EM skin biopsy showed normal results. When the girl had 10 years and 5 months and the boy 5 years and 8 months, NP-C was confi rmed by assaying cultured fi broblasts for cholesterol esterifi cation and staining for unesterifi ed cholesterol with fi lipin. At 10 years and 10 months, the girl had progression of demyelination with cortical atrophy, progressive deterioration with intractable epilepsy. At the age of 11 years, the girl was in vegetative state with insomnia, received PEG and died at 11 years and 10 months having permanent epileptic attacks despite antiepileptic polytherapy. The boy went to special school for two years and was not able to write and read. He had frequent epileptic attacks, dysarthria, ataxia, athetosis, spastic gait, slurred nasal and poor speech, followed by deterioration and death at the age of 10 years and 3 months. The parents had a third child, a healthy boy later diagnosed as heterozygous for the Gln922X mutation.
The studies of families with NP-C have shown that the affected siblings present a similar clinical course (1, 20) . However, diff erences between siblings bearing the same alleles are also described, e.g., patients with the perinatal form can have siblings with infantile-or juvenile-onset neurologic disease (9, 14, 21). As described here, in the boy we observed an earlier onset and a much faster neurologic deterioration (late infantile NP-C), suggesting other genetic and/ or environmental factors infl uencing the course of the disease. In contrast, the girl exhibited juvenile type of NP-C.
Due to the heterogeneous symptoms and age at onset, NP-C is often misdiagnosed (8, 11) . Even when clinical tests exclude other diseases, confi rmation of NP-C requires further biochemical and molecular-genetic laboratory tests. In the cases presented here, the diagnosis of NP-C in siblings was hampered by rarity of the disease leading to insuffi cient clinical awareness, as well as nonexistence of the required laboratory testing in Croatia. Therefore, with the extreme commitment of physicians and family, necessary tests were conducted in the University Medical Center, New York (skin biopsy for determination of lipid inclusions in dermal axons, E.H. Kolodny), Institut National de la Santé et de la Recherche Médicale, Lyon (fi lipin test and cholesterol esterifi cation in fi broblasts, M.T. Vanier) and Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze Modena (molecular genetic analyses, S. Calandra). It has to be noted that both biochemical tests in fi broblasts are necessary for accurate NP-C diagnosis, since reliance on one or the other may lead to the diagnosis being missed in some cases: the transport of cholesterol is studied by cholesterol esterifi cation studies and the storage of cholesterol is assessed by staining the cells with fi lipin, which glows under ultraviolet light (8, 21) . Skin biopsy of dermal axons was positive for lipid inclusions only in the female sibling. Therefore, this test has to be taken with caution. The diagnosis should be confi rmed in suspected cases by genetic testing (i.e. DNA sequencing) (9) .
At the time of the study, there was no disease-modifying therapy available for NP-C (8). Therefore, therapy was limited to supportive measures, including pharmacotherapy to alleviate neurologic symptoms, such as antiepileptic drugs. At the time, a combination of hypocholesterolemic drugs and low-cholesterol diet was suggested to alleviate the symptoms, but no amelioration of the neurologic disease was observed in the presented case, or in the literature (22) . It was recently shown that miglustat (N-butyldeoxynojirimycin; NB-DNJ; Zavesca®, Actelion Pharmaceuticals Ltd.) delays the onset of neurologic symptoms. This molecule acts as an inhibitor of glucosylceramide synthase, which glucosylates ceramide to form glucosylceramide, the fi rst step in the synthesis of glycosphingolipids (9) . Miglustat has the ability to cross the blood-brain barrier and to prolong survival in animal models of NP-C (23, 24) . Today, the European Union has extended the indication of miglustat to the treatment of progressive neurologic manifestations in adult and paediatric patients with NP-C, and the drug is now approved for this indication in several other countries as the fi rst specifi c treatment for NP-C that can slow down or stop the progression of neurologic symptoms (1, 8, 9) . The approval of miglustat was based on data from several studies that showed stabilization of the neurologic disease course in patients treated for one year or more (25) (26) (27) (28) . Regarding the cases presented here, the female sibling did not receive miglustat because at the time it was still under investigation and she was deteriorated and in vegetative state. Following insufficient information about the pharmacokinetics, effi cacy and safety in NP-C patients, the male sibling did not enter clinical trial in 2000.
In conclusion, in late childhood when progressive neurologic symptoms develop and with a previous history of neonatal cholestasis without known aetiology, a classic late infantile or juvenile type of NP-C must be suspected. A timely and accurate diagnosis is important because now it allows not only support and palliative care but also early miglustat therapy, as well as appropriate family counselling. 
